APVO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States...

Stats
Today's Volume	160 544
Average Volume	896 254
Market Cap	3.26M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-1.930 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.00700 (0.87%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Taylor Daphne	Buy	1 584	Common Stock
2024-03-02	Taylor Daphne	Buy	3 667	Common Stock
2024-03-02	Taylor Daphne	Sell	3 667	Restricted Stock Unit
2024-03-04	Taylor Daphne	Sell	1 584	Restricted Stock Unit
2024-03-03	Lamothe Jeffrey G.	Buy	3 667	Common Stock

INSIDER POWER
26.90
Last 99 transactions
Buy: 423 660 \| Sell: 158 934

Volume Correlation

Long: -0.15 (neutral)

Short: -0.25 (neutral)

Signal:(50.593) Neutral

Aptevo Therapeutics Inc Correlation

10 Most Positive Correlations
SIRI	0.961
HAIN	0.959
ALLR	0.958
AKTX	0.954
ARKO	0.951
LULU	0.951
HTLD	0.949
SHEN	0.949
CMTL	0.948
JACK	0.948

10 Most Negative Correlations
IVCB	-0.971
NKTR	-0.961
ENTX	-0.956
TZPSU	-0.955
TZPS	-0.954
VITL	-0.952
GALT	-0.951
IXAQ	-0.95
RZLT	-0.95
MPRA	-0.949

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aptevo Therapeutics Inc Correlation - Currency/Commodity

0.42
( neutral )

0.43
( neutral )

0.00
( neutral )

-0.06
( neutral )

Aptevo Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-567 000 (0.00 %)
EPS:	$-62.62

FY	2023
Revenue:	$0
Gross Profit:	$-567 000 (0.00 %)
EPS:	$-62.62

FY	2022
Revenue:	$3.11M
Gross Profit:	$2.21M (71.07 %)
EPS:	$368.10

FY	2021
Revenue:	$12.29M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-6.07

Financial Reports:

No articles found.

Aptevo Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.